Survivorship of the Neuflex silicone implant in MCP joint replacement.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19270002.
- Also identified by DOI 10.1177/1753193408094437.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Neuflex silicone metacarpophalangeal (MCP) joint replacement has previously been shown to provide improved movement, particularly flexion, when compared with the Swanson implant. In this study, we reviewed the outcome of 237 Neuflex implants in 66 patients with a follow-up of up to 7 years. Kaplan-Meier analysis using revision as the end stage revealed survival at 7 years to be 88%. If however an implant fracture, as seen radiographically, is taken as the end point, the survivorship drops to 68% at 7 years. These figures are comparable with a similar analysis for the Swanson implant. We conclude that the improved range of motion of the Neuflex implant demonstrated previously does not result in either a higher or a lower revision or implant fracture rate when compared with the Swanson implant.
Medical subject headings
- Equipment Failure Analysis
- Joint Prosthesis
- Metacarpophalangeal Joint
- Silicones
Anatomy
- hand